Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

708 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group. Herbst RS, et al. Among authors: johnson be, johnson dh. J Clin Oncol. 2005 Sep 1;23(25):5892-9. doi: 10.1200/JCO.2005.02.840. Epub 2005 Jul 25. J Clin Oncol. 2005. PMID: 16043829 Clinical Trial.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Schiller JH, et al. Among authors: johnson dh. N Engl J Med. 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954. N Engl J Med. 2002. PMID: 11784875 Free article. Clinical Trial.
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH; Eastern Cooperative Oncology Group. Eton DT, et al. Among authors: johnson dh. J Clin Oncol. 2003 Apr 15;21(8):1536-43. doi: 10.1200/JCO.2003.07.128. J Clin Oncol. 2003. PMID: 12697878 Clinical Trial.
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J. Miller VA, et al. Among authors: johnson dh. J Clin Oncol. 2003 Jun 1;21(11):2094-100. doi: 10.1200/JCO.2003.12.008. J Clin Oncol. 2003. PMID: 12775734 Clinical Trial.
708 results